Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Source And Potency Of Stem Cells01:27

Source And Potency Of Stem Cells

Stem cells are undifferentiated cells with extensive self-renewal properties that help them maintain their population during the fetal and adult stages of life. They can specialize in all cell types of the human body. However, their differential potential may vary and can be classified into five types. Stem cells can be (1) Totipotent, (2) Pluripotent, (3) Multipotent, (4) Oligopotent, and (5) Unipotent. Each stem cell has a specific origin; the fertilized egg or zygote is a totipotent cell and...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Embryonic Stem Cells00:57

Embryonic Stem Cells

Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
Adult Stem Cells01:33

Adult Stem Cells

Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously renew...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Marginalising dyslexic researchers is bad for science.

eLife·2023
Same author

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization.

Communications biology·2021
Same author

Lung Marginated and Splenic Murine Resident Neutrophils Constitute Pioneers in Tissue-Defense During Systemic <i>E. coli</i> Challenge.

Frontiers in immunology·2021
Same author

Bioglass/carbonate apatite/collagen composite scaffold dissolution products promote human osteoblast differentiation.

Materials science & engineering. C, Materials for biological applications·2020
Same author

Effect of the CXCR4 antagonist plerixafor on endogenous neutrophil dynamics in the bone marrow, lung and spleen.

Journal of leukocyte biology·2020
Same author

A Single 9-Colour Flow Cytometric Method to Characterise Major Leukocyte Populations in the Rat: Validation in a Model of LPS-Induced Pulmonary Inflammation.

PloS one·2016
Same journal

Mediastinal amyloidosis mimicking advanced lung cancer.

Thorax·2026
Same journal

Comparative performance of endobronchial ultrasound-guided sampling techniques in patients with mediastinal lesions: a network meta-analysis.

Thorax·2026
Same journal

Vitamin A and D impact on lung function: differential or common effects across the lifespan?

Thorax·2026
Same journal

The impact of vitamins A and D on lung function and regulatory epigenetics in adult and childhood asthma.

Thorax·2026
Same journal

Radiological factors associated with the recurrence of <i>Mycobacterium avium complex</i> pulmonary disease: a multicentre retrospective cohort study.

Thorax·2026
Same journal

Daughter vesicles in primary diaphragmatic hydatid cyst.

Thorax·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Isolation of Perivascular Multipotent Precursor Cell Populations from Human Cardiac Tissue
08:15

Isolation of Perivascular Multipotent Precursor Cell Populations from Human Cardiac Tissue

Published on: October 8, 2016

Mesenchymal stem cells.

Sara Rankin1

  • 1Leukocyte Biology Section, NHLI Division, SAF, Faculty of Medicine, Imperial College, Exhibition Rd, London SW72AZ, UK. s.rankin@imperial.ac.uk

Thorax
|May 5, 2012
PubMed
Summary
This summary is machine-generated.

Mesenchymal stem cells (MSCs) offer therapeutic potential for respiratory diseases through immune modulation and tissue repair. Clinical trials are underway for conditions like COPD, highlighting MSCs

More Related Videos

Isolating Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow
09:53

Isolating Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow

Published on: July 15, 2016

Related Experiment Videos

Last Updated: May 22, 2026

Isolation of Perivascular Multipotent Precursor Cell Populations from Human Cardiac Tissue
08:15

Isolation of Perivascular Multipotent Precursor Cell Populations from Human Cardiac Tissue

Published on: October 8, 2016

Isolating Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow
09:53

Isolating Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow

Published on: July 15, 2016

Area of Science:

  • Regenerative Medicine
  • Immunology
  • Pulmonology

Background:

  • Mesenchymal stem cells (MSCs) are multipotent stromal cells sourced from bone marrow, adipose tissue, and umbilical cords.
  • MSCs possess paracrine functions crucial for tissue regeneration and immune response modulation.
  • Their therapeutic applications are being explored for various respiratory conditions.

Purpose of the Study:

  • To summarize the key features of Mesenchymal stem cells (MSCs).
  • To highlight the therapeutic potential of MSCs in the context of respiratory diseases.
  • To review the current status of MSCs in preclinical and clinical research for lung conditions.

Main Methods:

  • Review of existing literature on Mesenchymal stem cells (MSCs) and their properties.
  • Analysis of preclinical data from murine models of respiratory diseases.
  • Overview of ongoing clinical trials investigating MSC-based therapies for lung diseases.

Main Results:

  • MSCs demonstrate efficacy in preclinical models of respiratory diseases.
  • Five clinical trials are currently evaluating MSC administration for respiratory diseases.
  • Key conditions targeted include Chronic Obstructive Pulmonary Disease (COPD) and emphysema.

Conclusions:

  • Mesenchymal stem cells (MSCs) show significant promise for treating respiratory diseases.
  • The paracrine effects of MSCs are central to their regenerative and immunomodulatory capabilities.
  • Further clinical investigation is warranted to establish MSCs as a viable therapeutic option for lung conditions.